医学
硬化疗法
经皮
外科
放射科
强力霉素
透视
生物
微生物学
抗生素
作者
M Travis Caton,Amanda Baker,Eric R Smith,Edgar F. Perez,Kafi Hemphill,Daniel Cooke,Christopher F. Dowd
标识
DOI:10.1136/jnis-2022-019255
摘要
Percutaneous sclerotherapy is an effective technique for treating lymphatic malformations of the head and neck, with clinical success rates exceeding 84%.1 Sodium tetradecyl, which damages lipid membranes and stimulates free radical-induced local damage, and doxycycline, which inhibits angiogenesis, have emerged as the safest and most effective of several available sclerosants.2–4 Although severe periprocedural morbidity is rare, temporary local complications are reported in 14% and skin necrosis or scarring in up to 0.8–5.8% of sclerotherapy procedures.5 As these lesions are frequently located in the face and/or neck, even minor complications can be disfiguring and must be avoided. This technical video describes a ‘dual-agent’ approach for percutaneous sclerotherapy of macrocystic lymphatic malformations using sodium tetradecyl as a ‘primer’ followed by doxycycline as a definitive sclerosant (video 1). This technique emphasizes meticulous backtable preparation and effective use of ultrasound and fluoroscopy to minimize complications. Video 1
科研通智能强力驱动
Strongly Powered by AbleSci AI